BioCentury | Apr 10, 2021
Politics, Policy & Law

DiLenge predicts biopharma companies will ‘take a hit’ in infrastructure bill

As he prepares to leave BIO after 15 years, Tom DiLenge previewed the urgent policy challenges the industry will face in the coming months, including pending drug price control legislation that could reshape...
BioCentury | Mar 6, 2021

How Bayer is building a cell and gene therapy business through deals

After spending the last year laying the groundwork for its entrance into cell and gene therapies through dealmaking, Bayer is expanding its external innovation search to new indications and earlier-stage...
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease. The combo...
BioCentury | Sep 24, 2020
Politics, Policy & Law

Trump contradicts Hahn, says White House will decide on COVID-19 vaccine rules

The Trump administration’s top public health officials spent Wednesday morning trying to persuade the Senate and the American people that career staff will make COVID-19 vaccine decisions free from political influence.  The heads of FDA...
BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | May 5, 2020
Product Development

As FDA tightens reins on COVID-19 antibody testing, Roche unveils test specs via EUA

FDA’s reversal of its hands-off policy on antibody tests for the novel coronavirus, coupled with its authorization of a highly anticipated test from Roche, is raising the bar for COVID-19 serology. Yet accessing enough patient...
BioCentury | Feb 15, 2020
Politics, Policy & Law

With Treasury’s CFIUS rules in effect, eyes on Commerce definitions

Although the finalized rules governing Treasury Department’s review of foreign investments in U.S. companies went into effect Thursday, ambiguity from the Commerce Department on what biotechnologies could merit mandatory filings means lingering uncertainty for biopharma....
BioCentury | Dec 11, 2019
Emerging Company Profile

Flagship’s Cellarity maps out network-based drug discovery

Cellarity debuted Tuesday with technology to leverage single cell data to identify compounds that trigger protective changes in molecular networks, without needing to pin their therapeutic effects onto a single target. With $50 million in...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. Sanofi (Euronext:SAN; NYSE:SNY)...
Items per page:
1 - 10 of 187